Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 987.00% | 60.98% | -42.82% | -86.75% | -96.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 987.00% | 60.98% | -42.82% | -86.75% | -96.25% |
| Cost of Revenue | 584.62% | 82.95% | -54.86% | -73.08% | -58.73% |
| Gross Profit | 2,413.64% | 41.34% | -34.26% | -89.15% | -99.11% |
| SG&A Expenses | -12.50% | 4.18% | 14.24% | -17.13% | -19.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.81% | 5.42% | -17.59% | -11.66% | -12.62% |
| Operating Income | 30.20% | 2.75% | 14.32% | -55.86% | -42.66% |
| Income Before Tax | 24.78% | 4.31% | 10.76% | 30.02% | -56.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.78% | 4.31% | 10.76% | 30.02% | -56.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.78% | 4.31% | 10.76% | 30.02% | -56.20% |
| EBIT | 30.20% | 2.75% | 14.32% | -55.86% | -42.66% |
| EBITDA | 30.23% | 2.74% | 14.32% | -56.32% | -42.83% |
| EPS Basic | 24.44% | 2.56% | 9.76% | 29.82% | -55.17% |
| Normalized Basic EPS | 25.00% | 4.00% | 11.54% | 28.57% | -55.56% |
| EPS Diluted | 24.44% | 2.56% | 9.76% | 29.82% | -55.17% |
| Normalized Diluted EPS | 25.00% | 4.00% | 11.54% | 28.57% | -55.56% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
